MA07.07 Validation Analysis of MET IHC as a Biomarker for Amivantamab-Lazertinib Response in Post-Osimertinib EGFR-Mutated NSCLC
Year: 2025
Type: conference-abstract
Source: Journal of Thoracic Oncology
Authors: B. Besse, P. Tomasini, B.C. Cho, Y. Wang, D.-W. Kim, C.-C. Lin, C.S. Baik, S.-H. Lee, S. Lu, L. Paz-Ares, R.E. Sanborn, J.C.-H. Yang, M. D’Arcangelo, M. Cruz-Correa, S. Michels, J.C. Curtin, X. Luo, Z. Anastasiou, I. Leconte, Z. Jiang, L. Trani, M. Baig, E. Felip
Institutions: Institut Gustave Roussy, Centre National de la Recherche Scientifique, Inserm, Aix-Marseille Université, Centre de Recherche en Cancérologie de Marseille, Hôpital de la Timone, Yonsei University, Yonsei University Health System, Yonsei Cancer Hospital, Sichuan University, West China Hospital of Sichuan University, Seoul National University, Seoul National University Hospital, Tainan Hospital, National Cheng Kung University, University of Washington, Fred Hutch Cancer Center, Samsung Medical Center, Sungkyunkwan University, Shanghai Jiao Tong University, Shanghai Chest Hospital, Hospital Universitario 12 De Octubre, Providence Portland Medical Center, National Taiwan University, Ospedale "Santa Maria delle Croci" di Ravenna, University of Puerto Rico, Medical Sciences Campus, University of Puerto Rico System, University of Cologne, University Hospital Cologne, Johnson & Johnson (United States), Janssen Research & Development (United States), Universitat Autònoma de Barcelona, Vall d'Hebron Institute of Oncology
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4415519119